Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CMV-Specific T Cells for GBM
NCT02661282Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2016
- Primary completion
- Feb 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes in glioblastoma (GBM) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 42 days, Immunological Effects in Tumor Tissue up to 4 years and 2 more. Started Jun 2016; status: completed.
02
Drugs
autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02661282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661282.